Yahoo
NasdaqCM - Delayed Quote USD

Virax Biolabs Group Limited (VRAX)

2.1100 +0.0800 (+3.94%)
At close: October 7 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for VRAX
  • Previous Close 2.0300
  • Open 2.0200
  • Bid 1.7900 x 100
  • Ask 2.4200 x 100
  • Day's Range 1.8300 - 2.1800
  • 52 Week Range 1.8300 - 21.7500
  • Volume 265,354
  • Avg. Volume 1,798,253
  • Market Cap (intraday) 2.838M
  • Beta (5Y Monthly) 1.39
  • PE Ratio (TTM) --
  • EPS (TTM) -13.4000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

viraxbiolabs.com

26

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VRAX
75.61%
S&P 500 (^GSPC)
13.97%

1-Year Return

VRAX
86.83%
S&P 500 (^GSPC)
16.19%

3-Year Return

VRAX
97.28%
S&P 500 (^GSPC)
81.08%

5-Year Return

VRAX
99.96%
S&P 500 (^GSPC)
77.32%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Statistics

View More

Valuation Measures

Annual
As of 6/23/2026
  • Market Cap

    1.99M

  • Enterprise Value

    -4.03M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    80.01

  • Price/Book (mrq)

    0.26

  • Enterprise Value/Revenue

    107.34

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -54.23%

  • Return on Equity (ttm)

    -78.65%

  • Revenue (ttm)

    12.42k

  • Net Income Avi to Common (ttm)

    -5.02M

  • Diluted EPS (ttm)

    -13.4000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.52M

  • Total Debt/Equity (mrq)

    5.65%

  • Levered Free Cash Flow (ttm)

    -3.48M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.1100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: